British pharmaceutical company GSK has announced encouraging results from trials of a new treatment for one of the most aggressive forms of lung cancer, offering fresh hope to patients with limited treatment options.
The London-based company has revealed early global trial results for a medicine called Ris-Rez, designed to treat extensive-stage small cell lung cancer - a particularly aggressive cancer that often spreads quickly and returns after treatment.
What do the results show?
In the latest trial, 61% of patients receiving the higher dose experienced a measurable reduction in their tumours, compared with 32% receiving a lower dose.
That means approximately six in ten patients responded to the higher-dose treatment, although the trial involved just 18 evaluable patients at that dose.
The medicine works by targeting a protein found on cancer cells and delivering a powerful cancer-fighting drug directly to them.
Why is this important?
Small cell lung cancer accounts for around 10-15% of lung cancer diagnoses worldwide. Around 70% of patients are diagnosed after the disease has already spread extensively.
Treatment options can be limited, particularly when the cancer returns. The new medicine could eventually provide another option for patients facing this difficult diagnosis.
Although the higher dose showed promising results, 42% of patients experienced severe side effects, most commonly affecting the blood. Researchers say the treatment's safety profile remains manageable, but further trials and larger studies are needed to establish its safety and long-term benefits.
Why it matters for Britain
GSK is one of Britain's leading pharmaceutical companies, with its headquarters in London.
These encouraging results highlight Britain's continued involvement in developing innovative medicines that could improve and potentially extend lives around the world.
The treatment is now being evaluated in a major international Phase III trial, bringing it another step closer to potentially becoming an approved cancer therapy.
